emitefur has been researched along with 2,6-dihydroxy-3-cyanopyridine in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (66.67) | 18.7374 |
| 1990's | 1 (33.33) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Fujii, S; Fukushima, M; Imaoka, T; Ohshimo, H; Shimamoto, Y; Shirasaka, T | 1 |
| Fujii, S | 1 |
| Hayashi, K; Imaoka, T; Kawaguchi, T; Kubo, M; Matsui, Y; Miyauchi, S; Utsunomiya, T | 1 |
3 other study(ies) available for emitefur and 2,6-dihydroxy-3-cyanopyridine
| Article | Year |
|---|---|
Antitumor activity of BOF-A2, a new 5-fluorouracil derivative.
Topics: Administration, Oral; Animals; Antineoplastic Agents; Fluorouracil; Mice; Mice, Inbred ICR; Pyridines; Rats; Sarcoma 180; Sarcoma, Yoshida | 1989 |
[BOF-A1 and BOF-A2, new 5-FU degradation-inhibitory agents].
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Floxuridine; Fluorouracil; Liver; Mice; Pyridines; Pyrimidines; Rats; Sarcoma 180; Sarcoma, Experimental; Sarcoma, Yoshida; Tegafur; Uracil | 1987 |
Oral administration of BOF-A2 to rats with lung transplanted tumors results in increased 5-fluorouracil levels.
Topics: Administration, Oral; Animals; Antineoplastic Agents; Disease Models, Animal; Drug Combinations; Drug Interactions; Fluorouracil; Lung; Lung Neoplasms; Male; Neoplasm Transplantation; Pyridines; Rats; Sarcoma, Yoshida; Tegafur; Transplantation, Heterologous; Uracil | 1994 |